Ocugen Inc (OCGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $280.88M
Last updated: Nov 17, 2026 at 11:05 AM ET
Ocugen Inc (OCGN) Competitors
The companies most similar to Ocugen are Opus Genetics (IRD), Oculis Holding AG Ordinary shares (OCS) and Ovid Therapeutics (OVID). By market cap, Ocugen ranks 9th of the 13 companies on this page; Neurogene (NGNE) is the largest at $495.37M.
Peer Comparison
OCGN's ROIC of 271.0% is above the peer median of -42.2%, and its revenue growth of 11.4% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Ocugen (OCGN) | $280.88M | N/A | 54.9x | 0.0% | 271.0% | 11.4% | 0.00% |
| Opus Genetics, Inc. (IRD) | $384.68M | N/A | 52.0x | 0.0% | -145.1% | -63.1% | 0.00% |
| Oculis Holding AG Ordinary shares (OCS) | $425.67M | N/A | N/A | 0.0% | N/A | -97.1% | 0.00% |
| Ovid Therapeutics Inc (OVID) | $479.38M | N/A | 335.8x | 0.0% | N/A | -88.3% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Atrium Therapeutics, Inc. Common Stock (RNA) | $162.00M | N/A | 3.3x | -180.9% | -44.5% | 24.2% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| enGene Therapeutics Inc. (ENGN) | $161.51M | N/A | N/A | 0.0% | -42.2% | 0.0% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Editas Medicine Inc (EDIT) | $334.92M | N/A | 5.6x | -145.0% | -42.3% | 37.4% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Peer median | $359.80M | N/A | 11.6x | 0.0% | -42.2% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Ocugen, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Opus Genetics, Inc. (IRD) | Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. | IRD competitors |
| Oculis Holding AG Ordinary shares (OCS) | Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. | OCS competitors |
| Ovid Therapeutics Inc (OVID) | Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. | OVID competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Atrium Therapeutics, Inc. Common Stock (RNA) | Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. | RNA competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
| enGene Therapeutics Inc. (ENGN) | enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery... | ENGN competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Editas Medicine Inc (EDIT) | Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. | EDIT competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
Frequently Asked Questions About OCGN
Who are Ocugen's main competitors?
The companies most similar to Ocugen include Opus Genetics (IRD), Oculis Holding AG Ordinary shares (OCS), Ovid Therapeutics (OVID), Rocket Pharmaceuticals (RCKT) and PepGen (PEPG), listed from the closest match.
Who is Ocugen's biggest competitor?
Neurogene (NGNE) is the largest of the similar companies at $495.37M; Opus Genetics (IRD) is the closest match by business profile, size, sector and industry.
How does OCGN stock compare with its competitors?
OCGN's P/S is 54.9x against a peer median of 11.6x; its net margin is 0.0% against a peer median of 0.0%.
Which of Ocugen's competitors pays a higher dividend?
Ocugen pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Ocugen bigger than its competitors?
No. Ocugen is 9th by market cap among the 13 companies on this page; the largest is Neurogene (NGNE) at $495.37M.
OCGN pages: Overview, Earnings, Forecast, Financials, Competitors